Prescript-Assist

A Probiotic – Prebiotic Complex

        Helping Bridge ~

                                                                         ~ The Gap!

 

Prescript-Assist (P-A)  couples a broad      spectrum probiotic that contains more than 29 soil-based, pH-resistant micro-flora (SBOs that may be found in a healthy GI track) – with a proprietary humic and fulvic-acid prebiotic complex – to help the body in addressing GI Track and other disorders (e.g., IBS, Crohn’s, Colitis etc. as well as Traveler’s and Antibiotic Induced Diarrhea).

   P-A’s efficacy has been demonstrated in both medical reports and peer-reviewed scientific literature.

 

Impact of Medication on GI Health: P-A helps address gastric upset – often associated with the use of medication – by re-establishing a positive balance of beneficial GI micro-flora in the gut. Contemporary research has increasingly associated IBDs with bacterial infections following prolonged antibiotic use (e.g., Colitis with C. dificille).  In this regard, it has been posited that a proper ratio of beneficial-to-pathogenic bacteria should be more than 85%-to-15%. Antibiotic use – and a host of other medications – often adversely alters this ratio.  This results in negative effects to the overall ecology of the gut- causing gastric distress.

 

Disruptions in the gut’s ecology have been associated with damage to the GI “mucosal” membrane and increased permeability.  This in turn may allow partially digested proteins, toxins, undigested food particles and infectious agents to penetrate the intestinal lining.  This ultimately may lead to a host of chronic issues (including allergic responses to food) which may increase the potential for local infections as well as adverse autoimmune reactions. Certainly, antibiotic and other medication-induced alterations in GI micro-flora are associated with both acute and chronic disorders which impact the patients’ Quality of Life.

 

END OF FRONT PANEL

 

 

 

Micro-flora, and their Mechanisms-of-Action: The surface lining of the intestines (Intestinal Mucosa) constitutes the largest immune structure in the human body (some authorities identify this as the “largest organ in the human body”).  More than 50% of immune-cells reside in the Intestinal Mucosa.  P-A’s beneficial micro-flora serve to improve intestinal tract function by: (1) protecting the body against pathogenic organisms (e.g., pathogenic bacteria and viruses), (2) facilitating production of anti-inflammatory components in the gut wall, (3) creating amino acids, hormones, and vitamins, and antioxidants -- thereby helping to maintain both overall intestinal-tract and general health/well-being.

 

Beneficial micro-flora, in the course of their symbiotic-synbiotic relationship, stimulate the spleen’s immunologic function. They produce natural (beneficial) antibiotic substances, i.e., anti-bacterial and anti-viral (e.g., bacteriocins , surfactins, hydrogen-peroxide, etc).  They also selectively enhance the mucosal cell’s production of interleukins (ILs) that directly increase cell-mediated immunity. Simply stated, beneficial micro-flora reinforce and strengthen your immune system.

 

Prescript-Assist™ (P-A) has been evaluated in a series of open-label and double-blind clinical studies. Initial open-label “Physician evaluations” indicated broad efficacy toward helping address IBS, Crohn’s, Colitis and other IBDs.  More recent open-label evaluations – in both human (ages 2 to 65 years) and canine patients – support P-A’s efficacy in resolving bacterial diarrhea more rapidly than with typically used antibiotic therapies.

 

Formal, placebo-controlled, double-blind, cross-over studies support P-A’s particular efficacy for IBS (Clinical Therapeutics 2005; 27: 755-761).  Post cross-over and one-year follow-ups evidenced even greater efficacies in the same patients with initial use at 4 - 6 weeks (1 cap twice daily -- (Clinical Therapeutics 2007; 29: 1153-1160).     Indeed, a linear increase in well being was seen in the extended 4-week use of P-A – with the complete remission of IBS in all patients, captured at the 14 +2 month follow-up.  (re: Rome II Criteria.)

 

END OF PANEL



SUMMARY OF LAST PANELS:

Mechanisms-of-Action among the Microflora Include:
The surface lining of the intestines (Intestinal Mucosa)
constitutes the largest immune structure in the human body
(some authorities identify this as the “largest organ in the
human body”). More than 50% of immune-cells reside in
the Intestinal Mucosa. P-A’s beneficial micro-flora serve to
improve intestinal tract function by: (1) protecting the body
against pathogenic organisms (e.g., pathogenic bacteria
and viruses), (2) facilitating production of anti-inflammatory
components in the gut wall, (3) creating amino acids,
hormones, and vitamins, and antioxidants
-- thereby
helping to maintain both overall intestinal-tract and
general health/well-being; especially when taken on a
routine basis.

Beneficial micro-flora, in the course of their symbiotic-
synbiotic relationship, stimulate the spleen’s immunologic
 function. They produce natural (beneficial) antibiotic
substances, i.e., anti-bacterial and anti-viral (e.g.,
bacteriocins, surfactins, hydrogen-peroxide
, etc).
They also selectively enhance the mucosal cell’s production
of interleukins (ILs) that directly increase cell-mediated
immunity. Simply stated,
beneficial micro-flora reinforce
and strengthen your immune system.

Prescript-Assist™ (P-A) has been evaluated in a
series of open-label and double-blind clinical studies.

Initial open-label “Physician evaluations” indicated broad
efficacy toward helping address IBS, Crohn’s, Colitis and
other IBDs. More recent open-label evaluations – in both
human (ages 2 to 65 years) and canine patients – support
P-A’s efficacy in resolving bacterial diarrhea more rapidly
than with typically used antibiotic therapies.

Formal, placebo-controlled, double-blind, cross-over
studies support
P-A’s particular efficacy for IBS (Clinical
Therapeutics
2005; 27: 755-761). Post cross-over and
one-year follow-ups evidenced even greater efficacies in
the same patients with initial use at 4 - 6 weeks (1 cap twice
daily -- (Clinical Therapeutics 2007; 29: 1153-1160).

Indeed, a linear increase in well being was seen in the
extended 4-week use of
P-A with the complete
remission of IBS in all patients, captured at the 14 +2
month follow-up. (re: Rome II Criteria.)

                Selected Research Abstracts

Prescript-Assist Probiotic-Prebiotic
Treatment  for Irritable Bowel Syndrome:
A Methodologically Oriented, 2-Week,
Randomized, Placebo-Controlled,
Double-Blind Clinical Study

Alvah C. Bittner, PhD, CPE; Robert M. Croffut, BA;
Mary C. Stranahan, DO, MA

Prescript-AssistTM Probiotic-Prebiotic
Treatment for Irritable Bowel Syndrome :
Post Cross-Over and One-Year Follow-up
 Analyses

Alvah C. Bittner, PhD, CPE; Robert M. Croffut, BA;
Mary C. Stranahan, DO, MA,and Titut N. Yokelson, PhD

Submitted March 2007